Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Inclusion Criteria: - Type 2 diabetes - Age min. 50 years at screening and concomitantcardiovascular, cerebrovascular or peripheral vascular disease or chronic renal failure orchronic heart failure OR age min. 60 years at screening and other specified risk factors ofcardiovascular disease - HbA1c: 7.0% or above - Anti-diabetic drug naive or treated withone or more oral anti-diabetic drugs (OADs) or treated with human NPH insulin orlong-acting insulin analogue or premixed insulin, alone or in combination with OAD(s)

Exclusion Criteria: - Type 1 diabetes - Use of a glucagon-like peptide-1 (GLP-1) receptoragonist (exenatide, liraglutide or other) or pramlintide or any dipeptidyl peptidase 4 (DPP-4) inhibitor within the 3 months prior to screening (trial start) - Use of insulinother than human NPH insulin or long-acting insulin analogue or premixed insulin within 3months prior to screening. Short-term use of other insulin during this period in connectionwith intercurrent illness is allowed, at Investigator's discretion